Paratek's Stock Gains After Nuzyra's Oral Regime Wins FDA Approval For Pneumonia

by Vandana Singh, Benzinga Editor

June 1, 2021 9:38 AM | 1 min read |

The FDA has approved Paratek Pharmaceuticals Inc's PRTK supplemental marketing application for the oral-only dosing regimen of Nuzyra for Community-Acquired Bacterial Pneumonia (CABP).
The approval of an oral-only dose regimen for NUZYRA represents a significant opportunity to treat patients in either the outpatient or primary care setting to potentially reduces/eliminates hospitalizations and the associated risk and costs from a hospital stay, the company said.
The FDA approved Nuzyra in 2018 as an antibiotic with both once-daily oral and intravenous formulations to treat CABP and acute bacterial skin and skin structure infections.
Price Action: PRTK shares are up 7.6% at $8.84 during the market session on the last check Tuesday.

Posted In: Biotech News Health Care Small Cap FDA General Briefs Pneumonia

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.